| Literature DB >> 30894599 |
Franz Schaefer1, Laura Benner2, Dagmara Borzych-Dużałka3, Joshua Zaritsky4, Hong Xu5, Lesley Rees6, Zenaida L Antonio7, Erkin Serdaroglu8, Nakysa Hooman9, Hiren Patel10, Lale Sever11, Karel Vondrak12, Joseph Flynn13, Anabella Rébori14, William Wong15, Tuula Hölttä16, Zeynep Yuruk Yildirim17, Bruno Ranchin18, Ryszard Grenda19, Sara Testa20, Dorota Drożdz21, Attila J Szabo22, Loai Eid23, Biswanath Basu24, Renata Vitkevic25, Cynthia Wong26, Stephen J Pottoore27, Dominik Müller28, Ruhan Dusunsel29, Claudia Gonzalez Celedon30, Marc Fila31, Lisa Sartz32, Anja Sander2, Bradley A Warady33.
Abstract
While children approaching end-stage kidney disease (ESKD) are considered at risk of uremic anorexia and underweight they are also exposed to the global obesity epidemic. We sought to investigate the variation of nutritional status in children undergoing chronic peritoneal dialysis (CPD) around the globe. The distribution and course of body mass index (BMI) standard deviation score over time was examined prospectively in 1001 children and adolescents from 35 countries starting CPD who were followed in the International Pediatric PD Network (IPPN) Registry. The overall prevalence of underweight, and overweight/obesity at start of CPD was 8.9% and 19.7%, respectively. Underweight was most prevalent in South and Southeast Asia (20%), Central Europe (16.7%) and Turkey (15.2%), whereas overweight and obesity were most common in the Middle East (40%) and the US (33%). BMI SDS at PD initiation was associated positively with current eGFR and gastrostomy feeding prior to PD start. Over the course of PD BMI SDS tended to increase on CPD in underweight and normal weight children, whereas it decreased in initially overweight patients. In infancy, mortality risk was amplified by obesity, whereas in older children mortality was markedly increased in association with underweight. Both underweight and overweight are prevalent in pediatric ESKD, with the prevalence varying across the globe. Late dialysis start is associated with underweight, while enteral feeding can lead to obesity. Nutritional abnormalities tend to attenuate with time on dialysis. Mortality risk appears increased with obesity in infants and with underweight in older children.Entities:
Mesh:
Year: 2019 PMID: 30894599 PMCID: PMC6426856 DOI: 10.1038/s41598-018-36975-z
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Patient and treatment baseline characteristics.
| Total population | BMI < 2.5th percentile | BMI 2.5th–85th pct | BMI > 85th pct | P | |
|---|---|---|---|---|---|
| N = 1001 | n = 89 | n = 715 | n = 197 | ||
| Country GNI per capita (1000$) | 27.1 ± 13.6 | 24.0 ± 13.2 | 27.0 ± 13.4 | 28.6 ± 14.5 | 0.03 |
| Age (yrs) | 8.5 ± 5.8 | 7.7 ± 5.9 | 8.7 ± 5.8 | 8.1 ± 5.8 | 0.18 |
| Male gender | 550 (55%) | 50 (56.2%) | 388 (54.3%) | 112 (56.9%) | 0.79 |
| Renal diagnosis | 0.24 | ||||
| CAKUT | 424 (42.4%) | 44 (49.4%) | 291 (40.7%) | 89 (45.2%) | |
| Glomerulopathy | 388 (38.8%) | 30 (33.7%) | 292 (40.8%) | 66 (33.5%) | |
| Other | 189 (18.9%) | 15 (16.9%) | 132 (18.5%) | 42 (21.3%) | |
| Comorbidities | 355 (35.5%) | 38 (42.7%) | 250 (35.0%) | 67 (34.0%) | 0.32 |
| eGFR at PD start (ml/min/1.73 m2) | 8.0 (5.3) | 7.3 (5.1) | 7.9 (5.2) | 8.8 (5.6) | 0.01 |
| Urine output (L/m2/d) | 0.61 (0.94) | 0.53 (0.85) | 0.63 (0.93) | 0.56 (1.05) | 0.80 |
| PD modality | 0.51 | ||||
| CAPD | 222 (22.6%) | 23 (25.8%) | 156 (21.8%) | 43 (21.8%) | |
| APD | 759 (77.4%) | 60 (67.4%) | 547 (76.5%) | 152 (77.2%) | |
| Other | 13 (1.3%) | 6 (6.7%) | 6 (0.8%) | 1 (0.5%) | |
| Biocompatible PD fluid use | 428 (42.8%) | 33 (37%) | 316 (44.2%) | 79 (40.1%) | 0.31 |
| Height SDS | −1.9 ± 1.7 | −1.6 ± 2.1 | −1.8 ± 1.6 | −2.3 ± 1.8 | <0.001 |
|
| |||||
| None | 595 (59.4%) | 54 (60.7%) | 428 (59.9%) | 113 (57.4%) | 0.01 |
| Oral nutritional supplements | 218 (21.8%) | 24 (27%) | 160 (22.4%) | 34 (17.3%) | |
| NG tube | 92 (9.2%) | 6 (6.7%) | 69 (9.6%) | 17 (8.6%) | |
| Gastrostomy | 96 (9.6%) | 5 (5.6%) | 58 (8.1%) | 33 (16.7%) | |
| Amino acid PD fluid use | 12 (1.2%) | 4 (4.5%) | 5 (0.6%) | 3 (1.5%) | 0.01 |
| Growth hormone use | 64 (6.4%) | 3 (3.4%) | 50 (7.0%) | 11 (5.6%) | 0.37 |
| Hemoglobin (g/L) | 10.8 ± 1.9 | 11.0 ± 2.1 | 10.8 ± 1.9 | 10.8 ± 1.8 | 0.61 |
| Serum albumin (g/l) | 35.8 ± 6.9 | 36.2 ± 5.4 | 35.6 ± 7.2 | 36.2 ± 6.6 | 0.512 |
| Blood urea (mg/dl) | 96 (63) | 93 (64) | 97 (63) | 93 (62) | 0.52 |
| Serum bicarbonate (mM) | 23.9 ± 4.3 | 23.7 ± 4.1 | 23.9 ± 4.2 | 24.2 ± 4.7 | 0.63 |
| Serum phosphorus (mM) | 1.8 ± 0.6 | 1.8 ± 0.6 | 1.8 ± 0.6 | 1.7 ± 0.6 | 0.20 |
Data are expressed as n (%), median (IQR) or mean ± SD.
Figure 1Regional variation of nutritional status at start of CPD, sorted by decreasing fraction of patients with BMI within normal range.
Figure 2Regional differences in supplementary feeding practices in 386 children <6 years, sorted by increasing fraction of patients without enteral feeding.
Figure 3Course of BMI SDS according to nutritional status at start of PD (green: normal BMI, blue: overweight/obese, red: underweight). Regression lines are based on a mixed model predicting BMI SDS from duration of PD, nutritional status at start of PD and their interaction.
Factors predicting prospective annualized change in BMI SDS.
| Parameter Estimate (SE) | P | ||
|---|---|---|---|
| Intercept | −0.056 | (0.259) | 0.89 |
| Duration of PD (years) | −0.060 | (0.036) | 0.09 |
| Glomerulopathy | −0.229 | (0.089) | 0.01 |
| Other | −0.364 | (0.110) | 0.001 |
| BMI SDS | −0.456 | (0.026) | <0.001 |
| Height SDS | 0.113 | (0.025) | <0.001 |
| % deviation from estimated dry weight | −0.040 | (0.014) | 0.01 |
| Serum albumin (g/L) | 0.015 | (0.006) | 0.02 |
| Oral | −0.195 | (0.090) | 0.03 |
| NGT | 0.122 | (0.133) | 0.36 |
| Gastrostomy | 0.633 | (0.132) | <0.001 |
Positive change means BMI SDS increase (702 patients, 1930 differences in BMI SDS).
Figure 4Survival of patients with underweight (BMI < 2.5th percentile) (red) and without underweight (BMI > 2.5th percentile) (green) at last observation (log-rank test: p = 0.03).
Risk factors for death on CPD.
| Estimate | (SE) | Hazard ratio | 95% Confidence Interval | P | |
|---|---|---|---|---|---|
| Comorbidity | 0.836 | (0.279) | 2.307 | [1.336, 3.987] | 0.001 |
| Age | −0.102 | (0.028) | 0.903 | [0.856, 0.954] | <0.001 |
| BMI SDS | 0.136 | (0.123) | 1.145 | [0.900, 1.457] | 0.27 |
| BMI SDS * Age | −0.028 | (0.015) | 0.973 | [0.945, 1.002] | 0.06 |
Figure 5Hazard ratios of death according to age and BMI SDS (reference: age = 0, BMI SDS = 0) for a patient with no comorbidities, based on Cox regression with time dependent variables age, BMI SDS, presence of comorbidities and the interaction of bmi sds and age.